Charles Albright

Chief Scientific Officer at Affinia Therapeutics

Charlie was most recently Chief Scientific Officer at Editas Medicine where his research group advanced the pioneering CRISPR gene editing platform and medicines from program inception to Investigational New Drug (IND). He has led research activities at both biotech and big pharma companies across a range of therapeutic areas including neurology, neuromuscular, cardiovascular, ophthalmology, and oncology. Prior to that, he was Vice President, Genetically Defined Diseases and Genomics at Bristol-Myers Squibb Company, where he was responsible for developing the group’s strategy and building a pipeline of novel therapeutics with a focus on central nervous system (CNS) and cardiovascular rare diseases. Prior to his career in industry, Charlie held academic positions at Vanderbilt University and Whitehead Institute for Biomedical Research. Charlie received a B.S. in chemical engineering and a Ph.D. in biology from Massachusetts Institute of Technology.

Location

Boston, United States

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


Affinia Therapeutics

1 followers

Affinia Therapeutics is working to methodically engineer durable gene therapies for people with devastating diseases.


Employees

51-200

Links